8:32AM ET 5/12/2023 MT NewswiresProtagonist Therapeutics (PTGX) said Friday data from phase 1 and preclinical studies showed oral drug candidate JNJ-2113 produced systemic...
9:14AM ET 4/05/2023 MT NewswiresHealth care stocks were steady premarket Wednesday. The Health Care Select Sector SPDR Fund (XLV) and the iShares Biotechnology ETF (IBB) were unchanged...
3:33AM ET 4/05/2023 MT NewswiresProtagonist Therapeutics (PTGX) said Tuesday it priced its underwritten public offering of 5 million common shares at $20 per share for gross proceeds of...
5:35PM ET 4/04/2023 MT NewswiresProtagonist Therapeutics (PTGX) said late Tuesday it launched a $100 million public offering of common shares. The biopharmaceutical company expects to...